Navigation Links
Schizophrenia mouse model should improve understanding and treatment of the disorder
Date:12/28/2009

AUGUSTA, Ga. Scientists have created what appears to be a schizophrenic mouse by reducing the inhibition of brain cells involved in complex reasoning and decisions about appropriate social behavior.

Findings by Medical College of Georgia scientists, published Dec. 28 in PNAS, elucidate the critical balance between excitation and inhibition of these cells that appears to go awry in schizophrenia. They also provide the first animal model for studying the disabling psychiatric disorder that affects about 1 percent of the population.

"We believe the mouse, which exhibits some of the same aberrant behavior as patients with this disorder, will help identify better therapies," said Dr. Lin Mei, a developmental neurobiologist who directs MCG's Institute of Molecular Medicine and Genetics. "We are doing testing to see if antipsychotic drugs already on the market are effective in treating the mouse."

MCG scientists made the mouse by deleting a candidate gene for schizophrenia, ErbB4, from interneurons, which are brain cells that help shower larger decision-making neurons, called pyramidal cells, with inhibition.

In their earlier work, they identified how ErbB4 and another candidate gene, neuregulin-1, work together to balance the activity of these pyramidal cells. They reported in Neuron in May 2007 that the two help keep a healthy balance between excitation and inhibition by increasing release of GABA, a major inhibitory neurotransmitter in the inhibitory synapses of the brain's prefrontal cortex. Seven years earlier, they showed the two also put a damper on excitatory synapses, communication points between neurons where the neurotransmitter glutamate excites cells to action.

To further test these findings, this time they altered the natural check and balance in cells directly involved with supplying pyramidal neurons with the inhibitor GABA. They did this by knocking out the ErbB4 gene in nearby chandelier and basket interneurons that supply GABA to pyramidal cells. "If we take out ErbB4 in these two interneurons, the neuregulin should have no effect because it can't promote GABA," Dr. Mei, Georgia Research Alliance Eminent Scholar in Neuroscience, said.

His postulation played out in the behavior of the mouse, who exhibited schizophrenia-like behavior including increased movement and impaired short-term memory. The scientists are still gathering data on the manic aspect of schizophrenia in their mice.

For example, both the normal and knockout mice learned they would find a food pellet in each arm of an eight-armed chamber but that if they went to the same arm for seconds, there were none. But the knockouts took longer to learn and finish the task. Knockouts also spent a lot more time sniffing and snooping around and revisiting empty arms.

In another test, knockouts couldn't or wouldn't - make the connection that a relatively low noise would be followed by a slightly louder one. When they treated the knockouts with diazepam, an anti-anxiety medication, they responded similarly to the normal mice: the first sound prepared them for the second.

Dr. Mei suspects that if he could look at the chandelier and basket interneurons in the prefrontal cortex of schizophrenics, he would also find something wrong with their usual role of sensing the need for the inhibitor GABA and supplying it to the pyramidal cells. "In schizophrenia, the baseline of the excitatory neurotransmitter is probably high," he said.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
2. Normal role for schizophrenia risk gene identified
3. Schizophrenia Gene May Have On/Off Switch
4. Potential new approach to treat cognitive impairments in schizophrenia
5. Schizophrenia candidate genes affect even healthy individuals
6. Hearing messages embedded in noise could be early sign of schizophrenia
7. People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter
8. US FDA approves ABILIFY for adolescent patients with schizophrenia
9. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. Genes Yield More Clues to Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Schizophrenia mouse model should improve understanding and treatment of the disorder
(Date:9/19/2017)... ... September 19, 2017 , ... The ... Canyon Ranch to its recently formed Corporate Roundtable, a group of individuals ... and a sustainable world. , Canyon Ranch is a unique collection of lifestyle-based ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... present, Mirixa Corporation recently unveiled the MirixaPro 6.0 platform. As the industry’s ... medication management services are delivered. Based on industry research and market feedback, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Driving Dynamics Inc., announced today it ... Training Industry Inc. as part of its mission to continually monitor the training marketplace ... first annual 2017 Top 20 Health and Safety Training Companies list was based on ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... by a neurosurgeon, has received a big bump in sales after recently ... is currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, RonnieColemanNutrition.com, RevNutrition.com and ...
(Date:9/19/2017)... New York (PRWEB) , ... September 19, 2017 , ... ... dentist, Dr. Andrew Sami, was recently named one of the best dentists in America ... lifestyle magazine for dental professionals nationwide. Every fall, the magazine features the best 40 ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
Breaking Medicine Technology: